SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992; 327: 14781484.
  • 2
    Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med. 2002; 346: 14171418.
  • 3
    Diehl V. Advanced Hodgkin's disease: ABVD is better, yet is not good enough! J Clin Oncol. 2003; 21: 583585.
  • 4
    Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease [see comments]. N Engl J Med. 1998; 339: 15061514.
  • 5
    Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol. 2002; 20: 630637.
  • 6
    Diehl V, Franklin J, Hasenclever D, et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 1998; 16: 38103821.
  • 7
    Johnston LJ, Horning SJ. Autologous hematopoietic cell transplantation in Hodgkin's disease. Biol Blood Marrow Transplant. 2000; 6: 289300.
  • 8
    Sureda A, Arranz R, Iriondo A, et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol. 2001; 19: 13951404.
  • 9
    Ng AK, Bernardo MV, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 2002; 100: 19891996.
  • 10
    Noble S, Goa KL. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs. 1997; 54: 447472.
  • 11
    Lucas JB, Horwitz SM, Horning SJ, Sayegh A. Gemcitabine is active in relapsed Hodgkin's disease. J Clin Oncol. 1999; 17: 26272628.
  • 12
    Zinzani PL, Bendandi M, Stefoni V, et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica. 2000; 85: 926929.
  • 13
    Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter Phase II study. J Clin Oncol. 2000; 18: 26152619.
  • 14
    Frei E III, Luce JK, Talley RW, Vaitkevicius VK, Wilson HE. 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of lymphoma. Cancer Chemother Rep. 1972; 56: 667670.
  • 15
    Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting [published erratum appears in J Clin Oncol. 1990;8:1602] [see comments]. J Clin Oncol. 1989; 7: 16301636.
  • 16
    Andersson BS, Luna MA, Yee C, Hui KK, Keating MJ, McCredie KB. Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia. Cancer. 1990; 65: 10791084.
  • 17
    Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1997; 80: 286291.
  • 18
    Joerger M, Gunz A, Speich R, Pestalozzi BC. Gemcitabine-related pulmonary toxicity. Swiss Med Wkly. 2002; 132: 1720.
  • 19
    Linskens RK, Golding RP, van Groeningen CJ, Giaccone G. Severe acute lung injury induced by gemcitabine. Neth J Med. 2000; 56: 232235.
  • 20
    Sauer-Heilborn A, Kath R, Schneider CP, Hoffken K. Severe non-haematological toxicity after treatment with gemcitabine. J Cancer Res Clin Oncol. 1999; 125: 637640.
  • 21
    Gupta N, Ahmed I, Steinberg H, Patel D, Nissel-Horowitz S, Mehrotra B. Gemcitabine-induced pulmonary toxicity: case report and review of the literature. Am J Clin Oncol. 2002; 25: 96100.
  • 22
    Jeter MD, Janne PA, Brooks S, et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys. 2002; 53: 394400.
  • 23
    Bredenfeld H, Fries S, Meisner M, et al. BAGCOPP—a follow up report on a pilot study with a modified BEACOPP regimen showing unexpected acute toxicity in patients with advanced-stage Hodgkin's disease [abstract]. Blood. 2002; 100: 295b.
  • 24
    Comis RL. Bleomycin pulmonary toxicity: current status and future directions. Semin Oncol. 1992; 19 (2 Suppl 5 ): 6470.
  • 25
    Willenbacher W, Mumm A, Bartsch HH. Late pulmonary toxicity of bleomycin. J Clin Oncol. 1998; 16: 3205.
  • 26
    Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003; 21: 607614.
  • 27
    Straus DJ, Yahalom J, Zelenetz AD, et al. Results of a prospective randomized trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) alone vs. ABVD + radiation therapy for early stage non-bulky Hodgkin's disease [abstract]. Blood. 2001; 98: 769a.